Biohaven Pharmaceutical Holding Company Ltd. Stock News

When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.

On November 17, 2025, Biohaven's Chief Accounting Officer, George Clark, acquired 17,000 shares of company stock. Mr. Clark's purchase was valued at approximately $144,800.

NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.

Biohaven (BHVN) narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending and steep share price declines. BHVN's pipeline includes Opakalim for depression and epilepsy, TRAP/MoDE degraders for IgA nephropathy and Graves' disease, and Taldefgrobep alfa for obesity and spinal muscular atrophy. Despite intriguing science and large market opportun...

NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.

NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd.

NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd.

Shares of Biohaven fell more than 40% on Wednesday after the U.S. Food and Drug Administration declined to approve its experimental treatment for a rare brain disorder.